An Epidemiological, Non-interventional Study to Evaluate Patient Compliance in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
- Postmenopausal females with estrogen receptor positive breast cancer that are
currently treated with aromatase inhibitor (AI) medication
- Provision of subject informed consent
- If participating in any clinical trial, the subject cannot take part in this study.
Type of Study:
Time Perspective: Prospective
Evaluate compliance rate, as assessed by investigator, after 12 months from baseline.
Outcome Time Frame:
Dr Jasna Pesic
M.D.spec of oncology, Institute for oncology Vojvodina, Sremska Kamenica
Serbia: Ethics Committee
- Hormon Receptor Positive Breast Cancer
- HR+ breast cancer
- Breast Neoplasms